CervoMed Inc. (CRVO): restructuring charge — Diffusion cuts nearly half of staff, pauses lead drug study; CMO departs

CervoMed Inc.

Reduction in force affecting 6 of 13 employees (~46% cut) as cash preservation measure.
Company pauses Phase 2 study of TSC in newly diagnosed GBM; evaluating sale or out-license of TSC.
Expects $1.1M one-time charge in Q1 2023 for termination benefits.
Chief Medical Officer Dr. Christopher Galloway departs effective March 1, 2023; separation includes 9 months salary, pro-rated bonus.

item 1.02 item 2.05 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher D. Galloway

Chief Medical Officer

CRVO · CervoMed Inc.

Effective: 2023-03-01
Filed: February 16, 2023, 6:59 PM ET

As part of the reduction in force, the Company determined that Dr. Christopher D. Galloway, M.D., the Company’s Chief Medical Officer, will depart Diffusion effective March 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher D. Galloway departed as Chief Medical Officer at CervoMed Inc..

Action: departed
Role: Chief Medical Officer

Exact text from the filing

As part of the reduction in force, the Company determined that Dr. Christopher D. Galloway, M.D., the Company’s Chief Medical Officer, will depart Diffusion effective March 1, 2023.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

CervoMed Inc. announced a restructuring with charges of approximately $1.1 million affecting clinical operations function (six of the Company’s 13 current employees).

Type: restructuring
Charge: approximately $1.1 million
Affected area: clinical operations function
Headcount: six of the Company’s 13 current employees

Exact text from the filing

Diffusion expects to record a one-time charge of approximately $1.1 million in the first quarter of 2023 in connection with the reduction in force, primarily related to one-time termination benefits to be paid in cash, which is expected to be completed in March 2023.

View on SEC.gov

Browse all restructurings & charges →

CervoMed Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-003646

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.